[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 106
1. Cantu de Leon D, Perez Montiel D, Tabarez A, Martinez RM, Cetina L: Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors. World J Surg Oncol; 2009;7:20
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors.
  • BACKGROUND: Synchronous gynecological tumors are rare; it is even rarer to find the rarest of gynecological tumors that of the fallopian tube, together with a histological sub-type as rare as verrucous cervix.
  • CASE PRESENTATION: We report a synchronic fallopian tube adenocarcinoma and a verrucous cervical cancer.
  • A 85-year-old woman with postmenopausal genital hemorrhage, endometrial biopsy was reported as squamous metaplasia, an exploratory laparotomy was performed finding a tubal tumor diagnosed as adenocarcinoma, a staging procedure was performed.
  • Final staging revealed IB1 cervical carcinoma and IA G3 fallopian tube carcinoma.
  • [MeSH-major] Carcinoma, Verrucous / pathology. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJOG. 2007 Apr;114(4):425-9 [17309544.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(6):501-2 [18179146.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):29-35 [16445606.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2000 Oct;63(10):765-9 [11076434.001]
  • [Cites] Pathol Res Pract. 1998;194(10):713-20 [9820868.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Ugeskr Laeger. 1993 Feb 22;155(8):565-6 [8451794.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1984 Apr;36(4):617-22 [6715942.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1050-4 [14674078.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(1):73-5 [12691323.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Jun;26(3):189-92 [10932980.001]
  • [Cites] Oncologist. 2006 Sep;11(8):902-12 [16951394.001]
  • [Cites] Arch Gynecol Obstet. 2008 Jun;277(6):557-62 [18066567.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6C):4491-4 [18214065.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):78-82 [17049712.001]
  • (PMID = 19222847.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2649116
  •  go-up   go-down


2. Sarangthem B, Laishram S, Sharma AB, Konjengbam R, Debnath K: Primary bilateral tubal adenocarcinoma associated with uterine leiomyomas. Indian J Pathol Microbiol; 2008 Jan-Mar;51(1):32-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bilateral tubal adenocarcinoma associated with uterine leiomyomas.
  • Primary adenocarcinoma of the fallopian tube is the least common primary malignant tumor of the female genital tract.
  • Often the diagnosis is mistaken for ovarian tumor or tubo-ovarian mass.
  • A case of bilateral primary tubal adenocarcinoma of serous type associated with uterine leiomyomas, without evidence of metastasis occurring in a postmenopausal woman is being reported.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / pathology. Leiomyoma / complications. Leiomyoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Hysterectomy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417847.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Babu MR, Haji AG, Chitrathara K, Vijaykumar DK, Samanta J, Hiran KR: Primary transitional cell carcinoma of the fallopian tube in a premenopausal woman: A case report and review of literature. Indian J Med Paediatr Oncol; 2009 Jan;30(1):35-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary transitional cell carcinoma of the fallopian tube in a premenopausal woman: A case report and review of literature.
  • Transitional carcinomas are extremely rare in the fallopian tube.
  • Pathological examination confirmed a primary transitional cell carcinoma of the left fallopian tube.
  • Review of available literature suggested that the primary transitional cell carcinoma is probably less aggressive compared to classical adenocarcinoma of the fallopian tube, and it has to be distinguished from the recently recognized entity, parafallopian tube transitional cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Jan;80(1):16-20 [11136563.001]
  • [Cites] Gynecol Oncol. 1987 Mar;26(3):305-13 [3557196.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):367-79 [10053109.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):469-75 [9887253.001]
  • [Cites] Cytojournal. 2005;2:20 [16336674.001]
  • [Cites] Oncologist. 2006 Sep;11(8):902-12 [16951394.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):121-9 [644422.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):379-83 [12217766.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2447-56 [8402462.001]
  • (PMID = 20668606.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2902214
  • [Keywords] NOTNLM ; Carcinoma ovary / fallopian tube / transitional cell carcinoma
  •  go-up   go-down


Advertisement
4. Goucha A, Rekik W, Debbabi B, Ben Mna N, Rahal K, El May A, Gammoudi A: [Primitive adenocarcinoma of the fallopian tube]. Tunis Med; 2010 Jul;88(7):523-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive adenocarcinoma of the fallopian tube].
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20582893.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


5. Buyukkurt S, Vardar MA, Zeren H, Guzel B, Tuncer I: Fallopian tube carcinoma metastatic to the pericardium and breast. Eur J Gynaecol Oncol; 2009;30(3):335-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube carcinoma metastatic to the pericardium and breast.
  • INTRODUCTION: Fallopian tube carcinoma is a rare gynecological tumor and simultaneous pericardial and breast metastasis of this cancer is an extremely exceptional event.
  • CASE: A 46-year-old woman with FIGO Stage IIIc, grade 3 adenocarcinoma of the fallopian tube received cyclophosphamide and carboplatin subsequent to surgery.
  • CONCLUSION: Although clinical and biological behavior and response to the treatment of fallopian tube carcinoma is quite similar to epithelial ovarian carcinoma, breast and pericardium are unusual sites of metastasis for each malignancy.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Fallopian Tube Neoplasms / pathology. Heart Neoplasms / secondary. Pericardium

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697636.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Limaiem F, Chelly I, Mekni A, Bellil S, Bellil K, Haouet S, Zitouna M, Kchir N: Challenging diagnosis: florid epithelial hyperplasia versus adenocarcinoma of the fallopian tube. Pathology; 2010 Jan;42(1):99-101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging diagnosis: florid epithelial hyperplasia versus adenocarcinoma of the fallopian tube.
  • [MeSH-major] Adenocarcinoma / diagnosis. Epithelial Cells / pathology. Fallopian Tube Diseases / diagnosis. Fallopian Tubes / pathology
  • [MeSH-minor] Adult. Curettage. Diagnosis, Differential. Fallopian Tube Neoplasms / diagnosis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025495.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


7. Brito LG, Marana HR, de Andrade JM, de Paula Philbert PM, Tiezzi DG, Zola FE: Primary adenocarcinoma of the fallopian tube as an incidental finding during surgery in a postmenopausal patient with unspecific pelvic pain. Eur J Gynaecol Oncol; 2009;30(5):597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the fallopian tube as an incidental finding during surgery in a postmenopausal patient with unspecific pelvic pain.
  • Primary fallopian tube carcinoma (PFTC) is a rare gynecologic neoplasm and is usually diagnosed late and presents classically with a characteristic group of symptoms.
  • During laparotomy, a mass located in the left tube was found.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Pelvic Pain / etiology

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899428.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Yogiraj SS, Vasantrao KP, Ranganthrao SB: Fallopian tube carcinoma. Indian J Pathol Microbiol; 2008 Apr-Jun;51(2):261-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube carcinoma.
  • Primary adenocarcinoma of Fallopian tube is a rare gynecological malignancy affecting women in the fifth and sixth decades of their lives.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603702.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Liapis A, Bakalianou K, Mpotsa E, Salakos N, Fotiou S, Kondi-Paffiti A: Fallopian tube malignancies: A retrospective clinical pathological study of 17 cases. J Obstet Gynaecol; 2008 Jan;28(1):93-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube malignancies: A retrospective clinical pathological study of 17 cases.
  • The histological type of all our specimens was primary papillary adenocarcinoma of the fallopian tube.
  • Primary fallopian tube cancer (PFTC) is a rare gynaecological malignancy, similar to ovarian cancer, but with poorer prognosis.
  • The PFTC should be considered in the differential diagnosis of any pelvic mass.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Fallopian Tube Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259909.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Maeda D, Takazawa Y, Ota S, Takeuchi Y, Seta A, Nakagawa S, Yano T, Taketani Y, Fukayama M: Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear. Int J Gynecol Pathol; 2010 May;29(3):273-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear.
  • Primary adenocarcinoma of the fallopian tube is an uncommon female genital tract tumor.
  • Here, we report a rare case of bilateral microscopic fallopian tube cancer that initially presented with malignant findings in an endometrial cytologic smear.
  • During the clinical diagnosis of endometrial cancer, she underwent bilateral salpingo-oophorectomy, total hysterectomy, and partial omentectomy.
  • In toto sectioning of the fallopian tubes and their fimbriated ends revealed minute foci of serous adenocarcinoma in the left tubal mucosa and right fimbria.
  • In situ adenocarcinoma components were present in both lesions.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407329.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, Legare R: Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest; 2010;69(4):270-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathology was typically benign; however, 15% showed ductal carcinoma in situ of the breast, 8% reported infiltrating ductal carcinoma of the breast, 3% was adenocarcinoma of the fallopian tube, and 3% was adenocarcinoma of the ovary.
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis Regulatory Proteins. Employment. Fallopian Tube Neoplasms / genetics. Fallopian Tube Neoplasms / prevention & control. Fallopian Tubes / surgery. Female. Humans. Marital Status. Mastectomy. Middle Aged. Ovariectomy. Parity. Patient Preference. Pregnancy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20090358.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


12. Nagao S, Oishi R, Iwasa N, Shimizu M, Hasegawa K, Goto T, Fujiwara K: A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma.
  • : e16549 Background: This is a feasibility study for a future trial to assess the feasibility of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin and IP paclitaxel (TCipTip therapy) in patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • METHODS: The patients eligible for this study had histologically confirmed, stage IC-IV epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • The patients included 7 epithelial ovarian carcinoma (stage IC, 2; stage IIIC, 5), 2 stage IIIC primary peritoneal carcinoma, and 1 stage IIA fallopian tube carcinoma.
  • There were 7 serous adenocarcinoma, 2 endometrioid adenocarcinoma, 1 clear cell adenocarcinoma.
  • CONCLUSIONS: TCipTip therapy is feasible for patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Rose PG, Drake R, Braly PS, Bell MC, Wenham RM, Hines JH, Alvarez-Secord A, Soltes-Rak E, Childs BH, Herzog TJ: Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol; 2009 May 20;27(15_suppl):5546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
  • : 5546 Background: Objectives are to estimate efficacy and safety of a novel taxane/platinum chemotherapy doublet in combination with bevacizumab (B), as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube (FT), after initial debulking surgery.
  • Tumors were mostly ovary as primary site (84%), poorly differentiated (65%), serous adenocarcinoma pathology (73%) and FIGO stage IIIC (68.2%) or IV (14.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962510.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Tanaka Y, Suzuki N, Takao M, Ichikawa A, Susumu N, Aoki D: Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma. Gynecol Oncol; 2005 Nov;99(2):500-3
Genetic Alliance. consumer health - Paraneoplastic cerebellar degeneration.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma.
  • BACKGROUND: Paraneoplastic cerebellar degeneration (PCD) is rarely caused by fallopian tube adenocarcinoma.
  • CASE: We present a patient with PCD and fallopian tube cancer.
  • CONCLUSION: This case highlights the importance of detecting the underlying malignancy in patients with subacute neurological impairment and shows that fallopian tube cancer can potentially cause PCD.
  • [MeSH-major] Adenocarcinoma / complications. Fallopian Tube Neoplasms / complications. Paraneoplastic Cerebellar Degeneration / etiology

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126258.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A24 Antigen
  •  go-up   go-down


15. Kalyani R, Kumar ML, Srikantia SH: Primary adenocarcinoma of fallopian tube--a case report. Indian J Pathol Microbiol; 2005 Apr;48(2):219-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of fallopian tube--a case report.
  • Primary adenocarcinoma of fallopian tube is the rarest gynecological malignancy of female genital system which is usually misdiagnosed as ovarian tumour or tubo-ovarian mass.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Fallopian Tubes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758673.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


16. Panda S, Patnaik A, Mishra B: Primary carcinoma of the fallopian tube--a case report. J Indian Med Assoc; 2008 Jul;106(7):460-1
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the fallopian tube--a case report.
  • After performing its role in procreation during the reproductive years, the fallopian tube harbours a malignancy during the postmenopausal years like any other reproductive organ and putting a diagnostic dilemma as to the source of primary focus.
  • A rare case of primary adenocarcinoma of fallopian tube is reported in a 71 years postmenopausal P6L5, presented with pain abdomen for 6 months, loss of appetite and abdominal distension for 4 months and on and off serosanguineous vaginal discharge for 1 month.
  • After clinical and laboratory evaluation it was provisionally diagnosed as a case of adenocarcinoma of ovary.
  • Exploratory laparotomy was carried out and the intra-operative diagnosis was fallopian tube carcinoma with intraperitoneal metastasis--surgical stage III disease.
  • Histopathology confirmed the diagnosis.
  • [MeSH-major] Adenocarcinoma. Fallopian Tube Neoplasms. Fallopian Tubes / pathology

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975502.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Kirshtein B, Meirovitz M, Okon E, Piura B: Sister Mary Joseph's nodule as the first presenting sign of primary fallopian tube adenocarcinoma. J Minim Invasive Gynecol; 2006 May-Jun;13(3):234-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as the first presenting sign of primary fallopian tube adenocarcinoma.
  • We describe the fourth case reported in the literature of Sister Mary Joseph's nodule originating from fallopian tube carcinoma.
  • Subsequent laparoscopy revealed a 2-cm friable tumor located at the fimbriated end of right fallopian tube and 1-cm peritoneal implant in the pouch of Douglas.
  • Because frozen section examination revealed fallopian tube carcinoma, the procedure was continued with laparotomy including total abdominal hysterectomy, omentectomy, and pelvic lymph node sampling.
  • Final diagnosis was stage IIIB fallopian tube carcinoma.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis. Umbilicus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698532.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


18. Monge AH, Pineda RP, del Rocio Estrada Hernandez M, Juárez EG, García JC: [Fallopian tube primary invasive adenocarcinoma associated with acute inflammatory pelvic disease. Case report and literature review]. Ginecol Obstet Mex; 2008 Feb;76(2):118-24
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fallopian tube primary invasive adenocarcinoma associated with acute inflammatory pelvic disease. Case report and literature review].
  • [Transliterated title] Adenocarcinoma invasor primario de trompa de falopio concomitante con enfermedad pélvica inflamatoria aguda. Comunicación de un caso y revisión de la bibliografía.
  • The primary fallopian tube invader adenocarcinoma is a preoperative diagnosis rarely reported in the literature, because is the most uncommon of all gynecological tumors, with prevalence from 0.3 to 1.8%.
  • In 25 to 60% of the cases a report of adenocarcinoma in the pap smear with negative endometrial biopsy can be found.
  • Fallopian tube malignancies are rare and involve a poor prognosis.
  • [MeSH-major] Adenocarcinoma / genetics. Fallopian Tube Neoplasms / complications. Pelvic Inflammatory Disease / complications

  • MedlinePlus Health Information. consumer health - Pelvic Inflammatory Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798405.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 3U02EL437C / Clindamycin; 75J73V1629 / Ceftriaxone
  • [Number-of-references] 10
  •  go-up   go-down


19. Longacre TA, Oliva E, Soslow RA, Association of Directors of Anatomic and Surgical Pathology: Recommendations for the reporting of fallopian tube neoplasms. Hum Pathol; 2007 Aug;38(8):1160-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recommendations for the reporting of fallopian tube neoplasms.
  • Primary malignancies of the fallopian tube are extremely uncommon, in part due to (admittedly arbitrary) definitional criteria.
  • By convention, epithelial tumors that involve the ovary or peritoneal surfaces are considered to have arisen either in the ovary or endometrium or, in absence of significant ovarian or endometrial involvement, in the peritoneum, irrespective of whether or not the fallopian tube mucosa is also involved.
  • Evidence from the World Health Organization and more recently, from case-control studies of BRCA mutation carriers suggests the fallopian tube may have a more direct role in the development of at least some of these carcinomas.
  • An alternative hypothesis for the origin of ovarian and peritoneal carcinoma has even been proposed, based on the concept of transport and implantation of malignant cells from the tube to the ovary and peritoneum.
  • Malignancies in the fallopian tube can therefore be classified as (1) arising primarily in the fallopian tube, either from preexisting endometriosis (or more rarely, a mature teratoma) or directly from tubal mucosa with metastasis to adjacent tissues;.
  • (2) arising in the ovary, endometrium, or peritoneum with metastasis to the tubal serosa or mucosa; or (3) arising primarily in the fallopian tube as well as in the ovary, endometrium, or peritoneum (simultaneous primary tumors).
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Health Planning Guidelines. Medical Records / standards. Pathology / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Apr;40(4):603-4 [19289185.001]
  • (PMID = 17270244.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ko ML, Jeng CJ, Chen SC, Tzeng CR: Sonographic appearance of fallopian tube carcinoma. J Clin Ultrasound; 2005 Sep;33(7):372-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic appearance of fallopian tube carcinoma.
  • Fallopian tube carcinoma is the least common of gynecological malignancies.
  • Transvaginal sonography revealed a cystic lesion of the fallopian tube with papillary projections, distinct from the ovary and uterus.
  • [MeSH-major] Adenocarcinoma, Papillary / ultrasonography. Fallopian Tube Neoplasms / ultrasonography. Fallopian Tubes / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc
  • (PMID = 16196007.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


21. Roncati L, Barbolini G, Ghirardini G, Rivasi F: Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report. Int J Surg Pathol; 2010 Dec;18(6):561-3
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report.
  • We report a mature solid teratoma of the fallopian tube in an elderly woman.
  • This mass was noted on CT scan and considered metastatic in nature since following a bioptical diagnosis of endometrial adenocarcinoma.
  • Neoplasms of the fallopian tube are very uncommon and this is the first Italian case to be added to about other 60 of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Teratoma / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282291.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ingec M, Erdogan F, Kumtepe Y, Isaoglu U, Gundogdu C, Kadanali S: Management of bilateral fallopian tube carcinoma coexistent with tuberculous salpingitis. J Obstet Gynaecol Res; 2005 Feb;31(1):65-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of bilateral fallopian tube carcinoma coexistent with tuberculous salpingitis.
  • Primary carcinoma of the fallopian tube is a rare gynecologic malignancy.
  • Chronic tubal inflammation is associated with primary carcinoma of the fallopian tube.
  • There are only a few reports on primary carcinoma of the fallopian tube coexisting with tuberculous salpingitis.
  • We are reporting a patient with both the primary carcinoma of the fallopian tube and tuberculous salpingitis, which were detected in bilateral fallopian tubes.
  • The histologic type was serous adenocarcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Fallopian Tube Neoplasms / diagnosis. Salpingitis / diagnosis. Tuberculosis, Female Genital / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15669995.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Batra S, Singh M, Wynn JS: An unusual case of primary fallopian tube carcinoma in pregnancy. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:365-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of primary fallopian tube carcinoma in pregnancy.
  • Fallopian tube carcinoma is the rarest of all female genital tract malignancies.
  • It presented as a large, rapidly growing adnexal mass at 9 weeks of gestation which was removed and found to be a papillary serous carcinoma of the fallopian tube.
  • A staging laparotomy in the postnatal period showed no spread of tumor, and in view of her age and desire for further pregnancies, her uterus and other ovary and tube were conserved.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Fallopian Tube Neoplasms / surgery. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515625.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Stewart SL, Wike JM, Foster SL, Michaud F: The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol; 2007 Dec;107(3):392-7
Genetic Alliance. consumer health - Fallopian Tube Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of primary fallopian tube cancer in the United States.
  • OBJECTIVE: The objective of this study was to report the incidence of primary fallopian tube carcinoma (PFTC) in the United States population and to describe associated demographic and clinical factors.
  • The majority (88%) of PFTCs were adenocarcinomas; serous adenocarcinomas accounted for 44% and endometrioid adenocarcinomas for 19% of adenocarcinoma diagnoses.
  • Essentially half (49.9%) of PFTCs were poorly differentiated; 89% were unilateral at diagnosis.
  • Stage at diagnosis was fairly evenly distributed among localized (36%), regional (30%), and distant (32%).
  • Although the demographic characteristics of PFTC are similar to those of ovarian cancer, stage at diagnosis and the stable trend observed in PFTC are in contrast to ovarian cancer.
  • [MeSH-major] Fallopian Tube Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Dec;107(3):386-7 [18053873.001]
  • (PMID = 17961642.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


25. Kuroda N, Inui Y, Ohara M, Hirouchi T, Mizuno K, Kubo A, Hayashi Y, Enzan H, Lee GH: Hyaline globule-like structures in undifferentiated sarcoma cells of malignant müllerian mixed tumor of the fallopian tube. Med Mol Morphol; 2007 Mar;40(1):46-9
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyaline globule-like structures in undifferentiated sarcoma cells of malignant müllerian mixed tumor of the fallopian tube.
  • Malignant müllerian mixed tumors (MMMTs) of the fallopian tube are very rare neoplasms, and we present such a case with unusual findings here.
  • At the time of operation, the main tumor was present predominantly in the fallopian tube.
  • The carcinoma showed moderately to poorly differentiated adenocarcinoma.
  • Finally, pathologists should keep in mind that undifferentiated sarcoma cells in MMMT of the fallopian tube may contain hyaline globule-like structures in the cytoplasm.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Hyalin / ultrastructure. Mixed Tumor, Mullerian / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Cell Differentiation. Cytoplasm / metabolism. Cytoplasm / ultrastructure. Eosine Yellowish-(YS) / metabolism. Fallopian Tubes / pathology. Female. Humans. Lysosomes / metabolism. Lysosomes / ultrastructure. Microscopy, Electron, Transmission. Middle Aged. Mixed Tumor, Malignant / pathology. Mixed Tumor, Malignant / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384990.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


26. Kuroda N, Moriki T, Oguri H, Maeda N, Toi M, Miyazaki E, Hiroi M, Fukaya T, Enzan H: Malignant müllerian mixed tumor (carcinosarcoma) of the fallopian tube: an immunohistochemical study of neoplastic cells. APMIS; 2005 Sep;113(9):643-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant müllerian mixed tumor (carcinosarcoma) of the fallopian tube: an immunohistochemical study of neoplastic cells.
  • At surgery a polypoid mass was observed in the fimbria of the left fallopian tube.
  • Proliferation of rhabdomyoblastic cells or spindle cells, as well as adenocarcinoma arising from the mucosa of the fallopian tube, was observed.
  • A diagnosis of malignant müllerian mixed tumor (MMMT) was made.
  • CD10 was expressed in adenocarcinoma, undifferentiated, spindle and rhabdomyoblastic cells.
  • Finally, our preliminary report suggests that MMMT of the fallopian tube may contain immature smooth muscle cells or cells with the myofibroblast-like immunohistochemical phenotype in the undifferentiated component.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Uterine Neoplasms / metabolism

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218942.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


27. Sakurai N, Tateoka K, Fukaya K, Terada T, Kubushiro K: Supraclavicular lymph node metastasis as the initial presentation of primary fallopian tube carcinoma. Int J Clin Oncol; 2010 Jun;15(3):301-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraclavicular lymph node metastasis as the initial presentation of primary fallopian tube carcinoma.
  • Supraclavicular lymph node metastasis is a rare presentation of primary fallopian tube carcinoma.
  • A biopsy was performed, and its findings confirmed metastatic adenocarcinoma.
  • Subsequent exploratory laparotomy revealed right fallopian tube carcinoma as the primary lesion; consequently, right salpingo-oophorectomy was performed.
  • Supraclavicular lymph node metastasis was thought to be, although rarely, the first manifestation of primary fallopian tube carcinoma (PFTC).
  • [MeSH-major] Adenocarcinoma / secondary. Fallopian Tube Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186558.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D: The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer; 2009 Jan;19(1):58-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The fallopian tube: primary site of most pelvic high-grade serous carcinomas.
  • This paper reviews the evidence that pelvic serous carcinoma originates from the fallopian tube mucosa and puts forward a theory that inflammation in the tube, caused by menstrual cytokines or infection, is critical to the genesis of these tumors.
  • Other risk factors for pelvic serous carcinoma will be reviewed, including oral contraceptive use, parity, infertility, and tubal ligation.Studies were identified for this review by searching the English language literature in the MEDLINE database between the years 1995 and 2007 using the following keywords: fallopian tube neoplasia, ovarian serous adenocarcinoma, pregnancy, oral contraceptive, infertility, pelvic inflammatory disease, cytokines, menstruation, and tubal ligation, followed by an extensive review of bibliographies from articles found through the search.The clinical implications of this theory are discussed, and a change in surgical practice is recommended, with salpingectomy at the time of simple hysterectomy.
  • Inflammatory markers could be detected in the vagina from the fallopian tube indicating possible chronic inflammation and a risk factor for mutagenesis leading to serous carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Ovarian Neoplasms / pathology. Pelvic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258943.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal
  • [Number-of-references] 85
  •  go-up   go-down


29. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066567.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Kocak M, Tasci Y, Boran N, Isikdogan S, Dilbaz B: Primary and bilateral tubal carcinoma is associated with long-standing granulomatous inflammation and primary infertility: a case report. J Obstet Gynaecol Res; 2010 Aug;36(4):912-5
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic surgical exploration and frozen section on the resected tubes revealed bilateral fallopian tube adenocarcinoma and then a staging laparotomy was performed.
  • Histopathological examination showed a primary bilateral Grade 2 tubal serous adenocarcinoma of Stage 1b associated with granulomatous salpingitis.
  • Primary fallopian tube carcinomas in young women are extremely rare gynecological tumors that are infrequently diagnosed prior to surgical exploration and their cause is unknown.
  • A definitive diagnosis could be made on the histopathological examination in our case with the evidence of chronic pelvic inflammation.
  • [MeSH-major] Adenocarcinoma / complications. Fallopian Tube Neoplasms / complications. Infertility, Female / complications

  • Genetic Alliance. consumer health - infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Obstet Gynaecol Res. 2010 Oct;36(5):1150. Muberra, Kocak [corrected to Kocak, Muberra]; Yasemin, Tasci [corrected to Tasci, Yasemin]; Nurettin, Boran [corrected to Boran, Nurettin]; Zuhal, Isikdogan [corrected to Isikdogan, Suhal];(9) Berna, Dilbaz [corrected to Dilbaz, Berna]
  • (PMID = 20666969.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


31. Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, Cass IA, Rose PG, Leath CA 3rd, Rutledge T, Blankenship D, Gold MA: Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol; 2007 Dec;107(3):398-403
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
  • OBJECTIVE: Primary carcinoma of the fallopian tube (PCFT) is a rare malignancy comprising 1% of genital tract cancers.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Dec;107(3):386-7 [18053873.001]
  • (PMID = 17997146.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Organoplatinum Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


32. Marcos Sánchez F, Sánchez Díaz E, Marrupe González D, Albo Castaño MI, Viana Alonso A, Juárez Ucelay F: [Carcinoma of the Fallopian tube: a case]. An Med Interna; 2006 Feb;23(2):83-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the Fallopian tube: a case].
  • Pathological study showed proliferative endometrium, bilateral follicular cysts and well differentiated serous adenocarcinoma located at fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566658.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


33. Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE: Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med; 2005 May;129(5):651-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
  • OBJECTIVE: We present an immunohistochemical survey of GLUT1 expression in benign and malignant fallopian tube epithelia, and compare serous carcinomas of the fallopian tube and ovary.
  • DESIGN: One hundred two routinely fixed and processed archival specimens (36 benign fallopian tubes, 29 primary tubal adenocarcinomas, and 37 primary ovarian adenocarcinomas) were immunostained with rabbit anti-GLUT1 and developed with streptavidin-biotin/diaminobenzidine.
  • On average, GLUT1 staining in primary fallopian tube cancers was less extensive than in primary ovarian adenocarcinomas.
  • CONCLUSIONS: GLUT1 immunostaining of fallopian tube adenocarcinomas was substantially stronger and more extensive than staining of benign tubal epithelium, consistent with previously described findings in carcinomas versus benign tissues from many primary sites.
  • [MeSH-major] Adenocarcinoma / metabolism. Fallopian Tube Neoplasms / metabolism. Fallopian Tubes / metabolism. Immunohistochemistry / methods. Monosaccharide Transport Proteins / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859637.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human
  •  go-up   go-down


34. Piura B, Meirovitz M: Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur J Gynaecol Oncol; 2005;26(4):386-90
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
  • PURPOSE OF INVESTIGATION: To report the experience of a single institution in the south of Israel with weekly carboplatin in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.
  • METHODS: The hospital records of ten patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma who had 2nd-line or later chemotherapy with weekly carboplatin between January 2003 and December 2004 were retrospectively reviewed.
  • CONCLUSION: Weekly carboplatin has considerable activity and low and well tolerated toxicity in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122184.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


35. Das TK, Raha K, Bandyopadhyay A, Dasgupta A, Ghosh D, Mondal AK: Malignant mixed mullerian tumour of the fallopian tube of heterologous variety--a case report. Indian J Pathol Microbiol; 2005 Jul;48(3):354-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumour of the fallopian tube of heterologous variety--a case report.
  • She was operated upon and gross examination revealed a proliferative growth in the fimbrial end of the right fallopian tube.
  • Microscopically the tumour comprised of adenocarcinoma and component of spindle cell stromal sarcoma with areas of chondrosarcoma as heterologous element.
  • A diagnosis of malignant mixed mullerian tumour of the fallopian tube, clinically FIGO stage III was made, which is extremely rare in available literature.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Fallopian Tubes / pathology. Mixed Tumor, Malignant / pathology. Mixed Tumor, Mullerian / pathology. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761749.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


36. Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ: What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother; 2009 Nov;21(5):566-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
  • The aim of this retrospective analysis was to investigate the efficacy and adverse effects of the monoclonal antivascular endothelial growth factor antibody bevacizumab (Avastin(R)) combined with chemotherapeutic agents in non-protocol patients with recurrent ovarian, fallopian tube, or primary peritoneal malignancies.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933049.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Taxoids; 2S9ZZM9Q9V / Bevacizumab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


37. Kietpeerakool C, Suprasert P, Srisomboon J, Pantusart A: Primary carcinoma of the fallopian tube: A clinicopathologic analysis of 27 patients. J Med Assoc Thai; 2005 Oct;88(10):1338-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the fallopian tube: A clinicopathologic analysis of 27 patients.
  • OBJECTIVES: To analyze the clinicopathologic features of women with primary fallopian tube carcinoma DESIGN: Descriptive cross sectional study MATERIAL AND METHOD: Twenty-eight women diagnosed with primary fallopian tube carcinoma treated at Chiang Mai University Hospital between January 1997 and December 2004.
  • RESULTS: During the study period, the primary fallopian tube carcinoma accounted for 0.48% of all gynecologic malignancies.
  • Mean age at diagnosis was 53 years (range, 38-76 years).
  • In all women, primary fallopian tube carcinoma could not be diagnosed preoperatively.
  • Histology were serous adenocarcinoma (70.4%), endometrioid adenocarcinoma (22.2%), undifferentiated adenocarcinoma (3.77%) and carcinosarcoma (3.7%).
  • CONCLUSION: Primary fallopian tube carcinoma is a rare gynecologic malignancy that has various and nonspecific presentations.
  • Definite diagnosis is usually made postoperatively.
  • This malignancy should be considered in differential diagnosis of peri- and postmenopausal women who present with complex adnexal mass, unexplained uterine bleeding, abnormal glandular cells on cervicovaginal smear and complicated pelvic inflammatory disease.
  • [MeSH-major] Carcinoma / pathology. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519376.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


38. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol; 2007 Feb;19(1):3-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The distal fallopian tube: a new model for pelvic serous carcinogenesis.
  • RECENT FINDINGS: The distal fallopian tube is emerging as an established source of many early serous carcinomas in women with BRCA mutations (BRCA+).
  • The emerging data offer compelling evidence for a model of 'fimbrial-ovarian' serous neoplasia, and call attention to the distal fallopian tube as an important source for this disease, the study of which could clarify pathways to cancer in both organs and generate novel strategies for cancer prevention.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Fallopian Tube Neoplasms / pathology. Genes, BRCA1. Peritoneal Neoplasms / etiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218844.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 43
  •  go-up   go-down


39. Deliveliotou A, Hassiakos D, Fotiou S, Karvouni E, Creatsas G: Primary fallopian tube carcinoma associated with ovulation induction; a case report. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1360-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma associated with ovulation induction; a case report.
  • Primary fallopian tube carcinoma (PFTC) is an uncommon malignancy, not previously associated with fertility drugs use.
  • Histologic examination showed a primary right fallopian tube endometrioid adenocarcinoma and bilateral adnexal endometriosis.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Ovulation Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217974.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Puig F, Lapresta M, Lanzon A, Crespo R: Fallopian tube carcinoma: incidental finding during surgery for acute pelvic inflammatory disease--case report. Eur J Gynaecol Oncol; 2006;27(5):526-7
MedlinePlus Health Information. consumer health - Pelvic Inflammatory Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube carcinoma: incidental finding during surgery for acute pelvic inflammatory disease--case report.
  • BACKGROUND: Primary carcinoma of the fallopian tube is a rare condition.
  • Preoperative diagnosis is difficult and in most cases it is an intraoperative finding or a histopathological diagnosis.
  • Histopathology showed a primary fallopian tube carcinoma.
  • CONCLUSION: Malignancy should be included in the differential diagnosis of pelvic inflammatory disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis. Pelvic Inflammatory Disease / surgery
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / therapy. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Middle Aged. Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139993.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


41. Singhal P, Odunsi K, Rodabaugh K, Driscoll D, Lele S: Primary fallopian tube carcinoma: a retrospective clinicopathologic study. Eur J Gynaecol Oncol; 2006;27(1):16-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma: a retrospective clinicopathologic study.
  • INTRODUCTION: Primary fallopian tube carcinoma is a rare tumor.
  • The aim of this study was to evaluate clinical characteristics and management of fallopian tube malignancies at a large tertiary care cancer institute.
  • METHODS: A retrospective review of the Tumor Registry was conducted to identify all primary fallopian tube carcinomas between 1980 and 2001.
  • RESULTS: Thirty-five patients had histology consistent with fallopian tube carcinoma.
  • The median age at diagnosis was 56 years.
  • The most common histology was adenocarcinoma in 16 (46%) patients.
  • CONCLUSIONS: Fallopian tube malignancies are rare and carry a poor prognosis.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Cause of Death. Fallopian Tube Neoplasms / mortality. Fallopian Tube Neoplasms / pathology. Second-Look Surgery / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550961.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Acikalin MF, Ozalp S, Yalcin OT, Peker B: Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review. Eur J Gynaecol Oncol; 2005;26(3):342-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review.
  • Malignant neoplasms of the fallopian tube are the rarest of the gynecologic cancers.
  • Papillary serous adenocarcinoma appears to be the most common histologic type.
  • On the contrary, mixed cell types of fallopian tube carcinoma have rarely been reported in the literature.
  • A case of mixed serous and endometrioid carcinoma of the fallopian tube is presented and the related literature is reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Mixed Tumor, Malignant / pathology

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991543.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 13
  •  go-up   go-down


43. Nezhat FR, DeNoble SM, Liu CS, Cho JE, Brown DN, Chuang L, Gretz H, Saharia P: The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers. JSLS; 2010 Apr-Jun;14(2):155-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers.
  • OBJECTIVES: To describe our experience with laparoscopic primary or interval tumor debulking in patients with presumed advanced ovarian, fallopian tube, or peritoneal cancers.
  • Women with presumed advanced (FIGO stage IIC or greater) ovarian, fallopian tube, or primary peritoneal cancers deemed appropriate candidates for laparoscopic debulking by the primary surgeon(s) were recruited.
  • CONCLUSIONS: Laparoscopy can be used for diagnosis, triage, and debulking of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer and is technically feasible in a well-selected population.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):624-9 [15350350.001]
  • [Cites] JSLS. 2004 Apr-Jun;8(2):133-9 [15119657.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1467-71 [8111714.001]
  • [Cites] Obstet Gynecol. 1994 May;83(5 Pt 2):899-901 [8159391.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] Gynecol Oncol. 1995 Sep;58(3):301-6 [7672696.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):25-33 [7557611.001]
  • [Cites] Obstet Gynecol. 1996 May;87(5 Pt 2):868-70 [8677119.001]
  • [Cites] Surg Laparosc Endosc. 1996 Feb;6(1):38-45 [8808559.001]
  • [Cites] Surg Endosc. 1997 May;11(5):427-30 [9153168.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):278-87 [10053096.001]
  • [Cites] Obstet Gynecol. 2004 Nov;104(5 Pt 2):1167-70 [15516439.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):72-6 [15589583.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):729-35 [15721418.001]
  • [Cites] Am J Obstet Gynecol. 2005 May;192(5):1614-9 [15902166.001]
  • [Cites] Am J Obstet Gynecol. 2005 Nov;193(5):1645-9 [16260204.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):455-61 [16325244.001]
  • [Cites] Curr Opin Obstet Gynecol. 2006 Aug;18(4):407-12 [16794421.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):409-13 [17275077.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:11-9 [18336393.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jan;200(1):83.e1-6 [19019337.001]
  • [Cites] Am J Surg. 2009 Feb;197(2):238-45 [18639228.001]
  • [Cites] J Minim Invasive Gynecol. 2009 May-Jun;16(3):250-62 [19321390.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):36-41 [10883022.001]
  • [Cites] Am J Obstet Gynecol. 2001 Dec;185(6):1314-7 [11744902.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):431-4 [12893213.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):972-92 [14527919.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):199-203 [15047236.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):650-4 [15350354.001]
  • (PMID = 20932362.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3043561
  •  go-up   go-down


44. Shimada K, Ohashi I, Hanafusa K, Shibuya H, Somekawa Y, Yamaguchi Y, Kikuchi M: A rare case of paraovarian cancer coexisting with cancer of the fallopian tube: magnetic resonance appearance. Acta Radiol; 2005 Aug;46(5):543-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of paraovarian cancer coexisting with cancer of the fallopian tube: magnetic resonance appearance.
  • In the present report, we describe a case of paraovarian cancer coexisting with cancer of the fallopian tube and the magnetic resonance features.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Fallopian Tube Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224934.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


45. Maeda D, Ota S, Takazawa Y, Ohashi K, Mori M, Imamura T, Nakagawa S, Yano T, Taketani Y, Fukayama M: Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Virchows Arch; 2010 Nov;457(5):597-608
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.
  • Previous studies in Western countries have revealed that mucosal carcinoma of the fallopian tube frequently coexists with pelvic (ovarian, tubal, and peritoneal) serous carcinomas, and early tubal carcinoma is now regarded as a possible origin of these tumors.
  • However, the relationship between early tubal carcinoma and non-serous ovarian cancer, such as clear cell adenocarcinoma, has not been studied in detail.
  • In this study, we sought to examine the coexistence of mucosal carcinoma of the fallopian tube in Japanese ovarian cancer cases.
  • We submitted the fallopian tubes in toto for histological examination in 52 ovarian carcinoma cases and three peritoneal serous carcinoma cases.
  • Mucosal carcinoma of the fallopian tube did not coexist with non-serous adenocarcinoma (n = 40).
  • In contrast, mucosal carcinoma of the fallopian tube was observed in six cases of ovarian serous adenocarcinoma and one case of peritoneal serous adenocarcinoma.
  • Finally, it is unlikely that early tubal lesions are involved in the carcinogenesis of clear cell adenocarcinoma and other non-serous adenocarcinomas.
  • [MeSH-major] Carcinoma / pathology. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20872013.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


46. Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Sato S, Terakawa N: Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube. Int J Clin Oncol; 2008 Oct;13(5):461-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube.
  • Malignant mixed müllerian tumors (MMMT) of the fallopian tube are extremely rare, and optimal therapy for them is unknown.
  • Pathological examination determined International Federation of Gynecology and Obstetrics (FIGO) stage IIIc MMMT of the right fallopian tube.
  • TC therapy may be effective for MMMT of the fallopian tube.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Mixed Tumor, Mullerian / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Ovariectomy

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18946759.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


47. Damayanti Z, Ali AB, Iau PT, Ilancheran A, Sng JH: The founder mutation BRCA1c.2845insA identified in a fallopian tube cancer patient: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:362-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The founder mutation BRCA1c.2845insA identified in a fallopian tube cancer patient: a case report.
  • Fallopian tube carcinoma is a very rare tumor, comprising less than 1% of all gynecologic cancers and found primarily in postmenopausal women.
  • We describe a case of a 42-year-old woman with fallopian tube cancer in which the founder mutation BRCA1c.2845insA was detected by mutational analysis.
  • We report an association between this founder mutation and fallopian tube cancer as part of the hereditary breast cancer syndrome in an Asian population.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fallopian Tube Neoplasms / genetics. Genes, BRCA1. Neoplastic Syndromes, Hereditary / genetics

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515624.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 11
  •  go-up   go-down


48. Alduaij A, Hansen K, Zhang C: Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report. Diagn Pathol; 2010;5:44
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report.
  • We report a rare case of primary lymphoma of fallopian tube in a 68-year-old woman who underwent total hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma.
  • The specimen showed a well-differentiated endometrioid adenocarcinoma with superficial myometrial invasion.
  • The left fallopian tube revealed a 1 cm nodule that histologically showed diffuse lymphoid follicles consisting of small cleaved lymphocytes and occasional larger cells.
  • The findings were consistent with a primary low grade follicular lymphoma of fallopian tube.
  • Our case suggests that primary lymphoma of fallopian tube may be associated with a favorable prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / pathology. Hysterectomy. Incidental Findings. Lymphoma, Follicular / pathology. Neoplasms, Multiple Primary. Ovariectomy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):384-6 [12217767.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):1-21 [16306779.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(4):394-401 [1774110.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):736-8 [15581994.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • (PMID = 20584306.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2905343
  •  go-up   go-down


49. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH: Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res; 2005 Sep 1;11(17):6116-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
  • During malignant transformation, different histotypes arise that resemble epithelial cells from normal fallopian tube, endometrium, and intestine.
  • EXPERIMENTAL DESIGN: Expression of 63,000 probe sets was measured in 50 ovarian cancers, in 5 pools of normal ovarian epithelial brushings, and in mucosal scrapings from 4 normal fallopian tube, 5 endometrium, and 4 colon specimens.
  • RESULTS: When compared with normal ovarian epithelial brushings, alterations in serous tumors correlated with those in normal fallopian tube (P = 0.0042) but not in other normal tissues.
  • CONCLUSION: Studies at a molecular level show distinct expression profiles of different histologies of ovarian cancer and support the long-held belief that histotypes of ovarian cancers come to resemble normal fallopian tube, endometrial, and colonic epithelium.
  • [MeSH-major] Colon / metabolism. Endometrium / metabolism. Fallopian Tubes / metabolism. Gene Expression Regulation, Neoplastic. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenoma, Mucinous / genetics. Cystadenoma, Mucinous / metabolism. Female. Gene Expression Profiling. Humans. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144910.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 83639; United States / NCI NIH HHS / CA / CA16772-28
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


50. Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS: Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol; 2009 Mar;112(3):444-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
  • METHODS: Women with adenocarcinoma by biopsy or cytology with stage III/IV (pleural effusions only) epithelial ovarian, fallopian tube or primary peritoneal carcinoma that presented with bulky disease were treated with neoadjuvant intravenous (IV) paclitaxel 175 mg/m2 and carboplatin AUC 6 q 21 daysx3 cycles followed by surgery (if >/=50% decrease in CA125).

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):327-31 [2351315.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1335-41 [2199620.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):103-6 [2010101.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):146-50 [1894174.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):166-72 [8418230.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(4):198-202 [8398914.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] Gynecol Oncol. 1994 Apr;53(1):33-7 [8175019.001]
  • [Cites] Obstet Gynecol Clin North Am. 1994 Mar;21(1):195-212 [8015764.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):93-9 [9889037.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):10-5 [15790431.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):480-90 [17166564.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):265-70 [18055006.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):271-5 [18164380.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2585-91 [11745193.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(3):235-8 [3542268.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):282-90 [3276825.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):347-58 [3134277.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Gynecol Oncol. 1990 Mar;36(3):306-11 [2180794.001]
  • (PMID = 19138791.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA35262; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / U10 CA035262; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS423205; NLM/ PMC3513943
  •  go-up   go-down


51. McCoubrey A, Houghton O, McCallion K, McCluggage WG: Serous adenocarcinoma of the sigmoid mesentery arising in cystic endosalpingiosis. J Clin Pathol; 2005 Nov;58(11):1221-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenocarcinoma of the sigmoid mesentery arising in cystic endosalpingiosis.
  • This case report describes a Mullerian serous adenocarcinoma arising within a multoloculated cyst lined by ciliated serous-type epithelium located in the sigmoid mesentery.
  • This was lined largely by benign ciliated serous-type epithelium but a focus of well differentiated serous adenocarcinoma projected into the lumen.
  • This is a unique case of multiple omental, peritoneal, and retroperitoneal cysts (classified as cystic endosalpingiosis), one of which developed a focus of serous adenocarcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / etiology. Cysts / complications. Fallopian Tube Diseases / complications. Mesentery. Peritoneal Neoplasms / etiology. Sigmoid Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2000 Feb;53(2):161-2 [10767837.001]
  • [Cites] Arch Gynecol Obstet. 2004 Dec;270(4):302-6 [14551796.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):399-400 [11328842.001]
  • [Cites] Histopathology. 2001 Dec;39(6):645-6 [11903588.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):944-6 [12378522.001]
  • [Cites] Histopathology. 2004 Feb;44(2):109-15 [14764054.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):97-9 [15084836.001]
  • [Cites] Obstet Gynecol Surv. 1972 Mar;27(3):133-46 [4614139.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):109-17 [7102891.001]
  • [Cites] Am J Clin Pathol. 1983 May;79(5):633-7 [6188369.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(3):179-88 [2475447.001]
  • [Cites] Eur J Radiol. 1993 Sep;17(2):115-6 [8223678.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):393-6 [8774644.001]
  • [Cites] Clin Radiol. 1998 Dec;53(12):916-8 [9867279.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):166-75 [9989843.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • (PMID = 16254118.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770769
  •  go-up   go-down


52. Erşahin C, Huang M, Potkul RK, Hammadeh R, Salhadar A: Mesonephric adenocarcinoma of the vagina with a 3-year follow-up. Gynecol Oncol; 2005 Dec;99(3):757-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the vagina with a 3-year follow-up.
  • BACKGROUND: Mesonephric adenocarcinoma of the vagina is exceedingly rare, with only one well-documented case in the literature.
  • Little is known regarding clinical presentation, pathological characteristics, therapy, or prognosis of the vaginal mesonephric adenocarcinoma.
  • The tumor was an adenocarcinoma with ductal and tubular pattern arising in a background of mesonephric remnants.
  • The right fallopian tube and one paravaginal lymph node were positive for metastases.
  • CONCLUSION: We report the second case of mesonephric adenocarcinoma of the vagina with metastasis to the right fallopian tube and to one paravaginal lymph node.
  • [MeSH-major] Adenocarcinoma / pathology. Mesonephroma / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Fallopian Tube Neoplasms / secondary. Female. Humans. Lymphatic Metastasis. Middle Aged

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137744.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Snyder MJ, Bentley R, Robboy SJ: Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol; 2006 Apr;25(2):155-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis.
  • Three of the 11 cases had tumor clusters in the fallopian tube lumen.
  • Another 13 cases also had clusters of tumor within the fallopian tube lumen, and all 16 cases had peritoneal spread (p<0.001).
  • Retrograde transtubal implantation as well LV invasion are two important mechanisms by which USC spreads; all cases with tumor clusters in the fallopian tube lumen had peritoneal spread.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / secondary. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Neoplasm Metastasis
  • [MeSH-minor] Fallopian Tubes / pathology. Female. Humans. Hysterectomy. Neoplasm Invasiveness. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Peritoneum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633065.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Mulvany NJ, Mitchell G, Allen DG: Adenocarcinoma cells in Pap smears. Pathology; 2009;41(5):411-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma cells in Pap smears.
  • Adenocarcinomas of the cervix, endometrium, fallopian tube and ovary may present with malignant cells in a Pap smear.
  • Consideration of all of these points in conjunction with an appreciation of the classical cytomorphology of endometrioid, serous and clear cell carcinomas should allow a correct diagnosis of extrauterine adenocarcinoma with a high degree of probability.
  • [MeSH-major] Adenocarcinoma / diagnosis. Genital Neoplasms, Female / diagnosis. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900079.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 106
  •  go-up   go-down


55. Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR: Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc; 2008 Aug;83(8):917-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.
  • There were 2 cases of confirmed malignancy (fallopian tube adenocarcinoma and spindle cell uterine carcinoma) for which PET results were negative.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Neoplasm / analysis. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18674476.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB: Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer; 2009 Dec 1;125(11):2721-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
  • The objective of this study was to evaluate the role of an in vitro drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer.
  • In conclusion, LDR to both platinum and taxane chemotherapy, as determined by an in vitro drug resistance assay, independently predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer, especially in those patients who undergo optimal primary cytoreduction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Assay / methods. Drug Resistance, Neoplasm. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / secondary. Bridged Compounds / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / mortality. Endometrial Neoplasms / secondary. Female. Humans. In Vitro Techniques. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage


57. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, Lopez KL, Nickle M, Brown JV 3rd: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):771-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343605.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


58. Daskalakis M, de Bree E, Giannikaki E, Tsousis S, Tsiftsis DD: Synchronous granulosa cell tumour of the ovary and fallopian tube adenocarcinoma: two rare gynaecological malignancies. Aust N Z J Obstet Gynaecol; 2006 Dec;46(6):558-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous granulosa cell tumour of the ovary and fallopian tube adenocarcinoma: two rare gynaecological malignancies.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis. Granulosa Cell Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116067.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


59. Montalto SA, Hakmi A, Moth P, Raju KS, Coutts M, Papadopoulos AJ, Devaja O: Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case? Eur J Gynaecol Oncol; 2009;30(1):35-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case?
  • OBJECTIVE: The purpose of this study was to investigate what proportion of cases showing a well differentiated endometrioid endometrial adenocarcinoma in the hysterectomy specimen removed at two UK cancer centres had adverse pathological features or advanced stage disease at the time of presentation.
  • STUDY DESIGN: Ninety-eight patients who were operated on at either the South East London Cancer Centre, London or the Kent Oncology Centre, Maidstone had a histological diagnosis of well differentiated (grade 1) endometrioid adenocarcinoma in their hysterectomy specimen.
  • RESULTS: Of the initial 98 cases, 65 patients (66.3%) were referred with a preoperative curettage showing a well differentiated endometrioid adenocarcinoma, 25 cases (25.5%) were referred with atypical endometrial hyperplasia, seven patients (7.1%) were referred with a moderately differentiated endometrioid adenocarcinoma, and one case (1.0%) was referred with a possible malignant mixed Mullerian tumour.
  • Subsequent histological examination of the hysterectomy specimens revealed that all of these cases had a well differentiated endometrioid adenocarcinoma.
  • There were ovarian metastases in one case and metastasis to one fallopian tube in another.
  • From our study, 33.6% of cases with a well differentiated endometrioid adenocarcinoma of the uterus were Stage Ic or more at the time of presentation; 12.2% were at least FIGO Stage Ic, eight patients (8.2%) were FIGO Stage IIa, seven patients (7.1%) were Stage IIb and six patients (6.1%) were Stage III.
  • Cases with a preoperative biopsy showing atypical hyperplasia or well differentiated adenocarcinoma should have a preoperative MRI scan or preferably an intraoperative frozen section examination to identify those cases with adverse pathological features which need to be fully staged with pelvic and paraaortic lymphadenectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317254.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


60. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol; 2006 Feb;30(2):230-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
  • A proportion of adenocarcinomas in prophylactic adnexectomies (bilateral salpingo-oophorectomies [BSOs]) from women with BRCA mutations (BRCA positive) occur in the fallopian tube.
  • Three were in the fimbria, one in both the fimbria and proximal tube, and one involved the ampulla.
  • Four were serous carcinomas, four were confined to the tube, and three were noninvasive (intraepithelial).
  • Investigative strategies targeting the fimbriated end of the fallopian tube should further define its role in the pathogenesis of familial and sporadic ovarian serous carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Genetic Predisposition to Disease. Ki-67 Antigen / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434898.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


61. Wojnar A, Drożdż K, Dzięgiel P: Cavernous haemangioma of the oviduct. Pol J Pathol; 2010;61(2):103-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the fallopian tube haemangiomas are rare.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Fallopian Tubes / pathology. Hemangioma, Cavernous / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Humans. Leiomyoma / pathology. Leiomyoma / surgery. Neoplasms, Multiple Primary. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924995.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


62. Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhommé C: Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol; 2010 Feb;116(2):157-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
  • OBJECTIVE: This phase II investigated efficacy and tolerability of gefitinib in combination with paclitaxel (P) and carboplatin (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20109725.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib
  •  go-up   go-down


63. Mikami M, Kuwabara Y, Tanaka K, Komiyama S, Ishikawa M, Hirose T: Malignant mixed müllerian tumor of primary mesenteric origin. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1249-53
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently encountered an MMMT of primary mesenteric origin associated with left fallopian tube cancer.
  • When cases of peritoneal MMMT were reviewed, the disease was found to be associated with synchronous or metachronous gynecologic tumors of müllerian duct origin (ie, ovarian tumors, primary serous carcinoma of the peritoneum, fallopian tube cancer, endometrial cancer, and adenocarcinoma of the cervix) in 12 out of 32 patients (37.5%).
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Mixed Tumor, Mullerian / pathology. Neoplasms, Multiple Primary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343225.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Iavazzo C, Vorgias G, Kalinoglou N: Accidential detection of salpinx carcinoma after omphalocele repair. Bratisl Lek Listy; 2008;109(2):71-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Carcinoma of the fallopian tube is a rare disease accounting for < 1% of all gynecologic malignancies.
  • CASE: We present the first case of an accidental diagnosis of fallopian tube carcinoma after omphalocele repair.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis. Hernia, Umbilical / surgery. Incidental Findings

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457313.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


65. Junaid I, Paz R, Salihu HM, Sharma PP, Aliyu ZY: Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors. Arch Gynecol Obstet; 2006 Feb;273(5):315-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination confirmed a right ovarian carcinoid tumor embedded within a mature cystic teratoma while the left ovary, fallopian tube and the uterus contained a poorly differentiated adenocarcinoma of the endometrium.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Asthma / complications. CA-125 Antigen / blood. Carcinoid Tumor / complications. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Endometrial Neoplasms / complications. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Hydrothorax / complications. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Teratoma / complications. Teratoma / pathology. Teratoma / surgery. Uterine Neoplasms / complications. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136360.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


66. Lai CR, Hsu CY, Tsay SH, Li AF: Clinical significance of atypical glandular cells by the 2001 Bethesda System in cytohistologic correlation. Acta Cytol; 2008 Sep-Oct;52(5):563-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some characteristic background cytologic findings were also noticed in most cases of endometrial, fallopian tube and endocervical adenocarcinoma.
  • CONCLUSION: A diagnosis of AGC is more clinically significant by the 2001 Bethesda System, especially the "AGC, favor neoplastic" category.
  • [MeSH-major] Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Ovarian Neoplasms / pathology. Precancerous Conditions / pathology. Rectal Neoplasms / pathology. Urinary Bladder Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Female. Humans. Middle Aged. Papanicolaou Test. Retrospective Studies. Sarcoma, Endometrial Stromal / pathology. Vaginal Smears / methods

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Cytol. 2009 Jan-Feb;53(1):121
  • (PMID = 18833818.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Lax S: [Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria]. Pathologe; 2009 Dec;30 Suppl 2:210-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serous carcinomas develop at various sites of the Mullerian system, in particular, the ovaries, the peritoneum, the uterus and the fallopian tubes.
  • Whereas in the ovaries both pathways may occur and develop from inclusions of the surface epithelium, the fallopian tube has recently been described as an important site for the type II pathway.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / genetics. Fallopian Tube Neoplasms / pathology. Genital Neoplasms, Female / genetics. Genital Neoplasms, Female / pathology. Peritoneal Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Apoptosis Regulatory Proteins. BRCA1 Protein / analysis. BRCA1 Protein / genetics. BRCA2 Protein / analysis. BRCA2 Protein / genetics. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Cystadenoma / genetics. Cystadenoma / pathology. DNA Mutational Analysis. Fallopian Tubes / pathology. Female. Genitalia, Female / pathology. Germ-Line Mutation. Humans. Neoplasm Staging. Ovary / pathology. Tumor Suppressor Protein p53 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859709.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


68. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • Oct4 overexpression was associated with more advanced FIGO stage and higher histological grade in serous adenocarcinoma.
  • Conversely, Oct4 expression did not differ among mucinous lesions or correlate with clinicopathological parameters in patients with mucinous adenocarcinoma.
  • CONCLUSION: Results suggest that Oct4 expression may contribute to the initiation, promotion and progression of serous ovarian carcinoma; it might be a useful biomarker for the diagnosis and outcome prediction of serous ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


69. Ma CJ, Yang SF, Huang CC, Chai CY, Cheng KI, Tsai EM, Wang JY: Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review. Eur J Gynaecol Oncol; 2008;29(3):289-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, among the cases reviewed, MMMTs tend to be associated with synchronous or metachronous colonic cancer or gynecologic tumors originating from the müllerian duct, including ovarian tumors, fallopian tube cancer, endometrial cancer, cervical cancer, and serous carcinoma of the peritoneum (14 out of 43 patients; 32.6%).
  • [MeSH-major] Adenocarcinoma / surgery. Mesentery / pathology. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Middle Aged. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Postmenopause


70. Rieck GC, Lim K, Rogers MT, France E, Gray JR, Amso N, Evans AS, Howells RH, Fiander AN: Screening for familial ovarian cancer--management and outcome of women with moderate to high risk of developing ovarian cancer. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:86-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology of the women who had surgery showed three cases of malignancies (fallopian tube carcinoma, atypical ovarian epithelial cells, and metastatic breast cancer).
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Fallopian Tube Neoplasms / diagnosis. Neoplastic Syndromes, Hereditary / diagnosis. Ovarian Neoplasms / diagnosis. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515573.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M: Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res; 2009 Aug;29(8):2875-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Ascites and plasma were obtained from ovarian, primary peritoneal or fallopian tube cancer patients.
  • [MeSH-major] Ascites / immunology. Fallopian Tube Neoplasms / immunology. Ovarian Neoplasms / immunology. Peritoneal Neoplasms / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adult. Aged. Aged, 80 and over. Antigen-Presenting Cells / immunology. Antigen-Presenting Cells / metabolism. Antigen-Presenting Cells / pathology. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Chromium / metabolism. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Cytokines / metabolism. Endometrial Neoplasms / immunology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661290.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cytokines; 0R0008Q3JB / Chromium
  •  go-up   go-down


72. Kawano Y, Kaku T, Sonoda K, Hirakawa T, Kobayashi H, Ohishi Y, Nakano H: Expression of RCAS1 in female genital organs. Int J Gynecol Pathol; 2005 Oct;24(4):330-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Receptor-binding antigen expressed on a human uterine adenocarcinoma cell line, SiSo (RCAS1), has been reported to be a prognostic factor of various malignant tumors, and it has also been proven to induce apoptosis of lymphoid cells.
  • Immunohistochemical staining using anti-RCAS1 and anti-MIB-1 antibodies was performed on 123 surgical specimens of a histologically normal uterus, ovary, or fallopian tube from 66 patients, and the apoptotic index was determined.
  • [MeSH-minor] Adult. Aged. Aging. Antibodies, Antinuclear. Antibodies, Monoclonal. Apoptosis. Endometrium / chemistry. Epithelium / chemistry. Fallopian Tubes / chemistry. Female. Humans. Immunohistochemistry. Middle Aged. Ovary / chemistry. Stromal Cells / cytology. Uterus / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175077.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human; 0 / MIB-1 antibody
  •  go-up   go-down


73. Niu HL, Pasha TL, Pawel BR, LiVolsi VA, Zhang PJ: Thyroid transcription factor-1 expression in normal gynecologic tissues and its potential significance. Int J Gynecol Pathol; 2009 Jul;28(4):301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is highly expressed in normal and neoplastic thyroid and lung tissues, and is considered a reliable marker for lung adenocarcinoma and thyroid carcinoma.
  • Twenty-eight endometria (12 proliferative, 11 secretory, and 5 inactive), 26 fallopian tubes, 28 cervixes (14 endocervical and 14 ectocervical), 14 myometria, and 12 ovaries were studied.
  • In addition, 4 normal fallopian tubes and 2 ovaries from 5 pediatric patients (aged from 3 mo to 11-yr old) were evaluated.
  • Variable TTF-1 nuclear reactivity was identified in 25 of 26 (96%) fallopian tubes (extent of positivity ranged from 2% to 60%, median 25%), 15 of 28 (54%) endometria (1% to 10%, median 5%), and 6 of 14 (43%) endocervical samples (<5%).
  • TTF-1 was also identified in 2 of 4 (50%) pediatric fallopian tubes with 5% and 20% of the tubal epithelium being positive, respectively.
  • No TTF-1 expression was detected in ovarian tissue (neither epithelial nor stromal tissue; neither adult nor pediatric samples), ectocervical squamous epithelium or myometrium, nor in stromal tissue in endometrium, tube, or cervix.
  • TTF-1 might have a functional and developmental role in normal fallopian tube and endometrium, as it is highly expressed in tubal epithelium of both adults and young children, and in functional endometrium but not in inactive endometrium.
  • [MeSH-major] Cervix Uteri / metabolism. Endometrium / metabolism. Fallopian Tubes / metabolism. Myometrium / metabolism. Nuclear Proteins / biosynthesis. Ovary / metabolism. Transcription Factors / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483637.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


74. Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, McDonald JF: Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics; 2009;2:71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serous subtype of ovarian adenocarcinoma in humans has been hypothesized to arise from at least two possible classes of progenitor cells: the ovarian surface epithelia (OSE) and/or an as yet undefined class of progenitor cells residing in the distal end of the fallopian tube.
  • The results of the gene expression analyses were randomly confirmed in paraffin embedded tissues from ovarian adenocarcinoma of serous subtype and non-neoplastic ovarian tissues using immunohistochemistry.
  • RESULTS: Consistent with multipotent capacity, genes in pathways previously associated with adult stem cell maintenance are highly expressed in ovarian surface epithelia and are not expressed or expressed at very low levels in serous ovarian adenocarcinoma.
  • Among the over 2000 genes that are significantly differentially expressed, a number of pathways and novel pathway interactions are identified that may contribute to ovarian adenocarcinoma development.
  • CONCLUSIONS: Our results are consistent with the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as the origin of ovarian adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adult Stem Cells / metabolism. Adult Stem Cells / pathology. Cell Cycle / genetics. Cell Transformation, Neoplastic / genetics. Female. Frozen Sections. Gene Expression Regulation, Neoplastic. Humans. Lasers. Microdissection. Phenotype. Signal Transduction / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Feb;232(2):277-80 [17259335.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1971-82 [17043662.001]
  • [Cites] J Cell Biochem. 2007 May 1;101(1):9-33 [17340614.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2708-18 [17525203.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10063-8 [17553962.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4083-91 [17634533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15418-23 [17881565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15436-41 [17881570.001]
  • [Cites] J Pathol. 2007 Oct;213(2):131-9 [17724792.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2907-18 [17761946.001]
  • [Cites] Hum Reprod. 2008 Jan;23(1):129-38 [18000169.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):11-22 [18167336.001]
  • [Cites] Development. 2008 Feb;135(3):411-24 [18192283.001]
  • [Cites] Curr Biol. 1999 Dec 2;9(23):1415-8 [10607566.001]
  • [Cites] Cancer Lett. 2001 Feb 10;163(1):131-9 [11163117.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):226-40 [11157778.001]
  • [Cites] J Biol Chem. 2001 Jan 19;276(3):1881-8 [11038359.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11347-52 [11572986.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8196-205 [12444557.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1235-41 [12649182.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3775-81 [12824416.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):491 [12893227.001]
  • [Cites] Development. 2004 Mar;131(5):965-73 [14973298.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E7 [14737219.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2648-57 [15007381.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Jun;229(6):546-52 [15169974.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):444-54 [15070830.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1117-21 [15378062.001]
  • [Cites] Biol Reprod. 2004 Nov;71(5):1501-7 [15229142.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Environ Health Perspect. 1993 Dec;101 Suppl 5:15-26 [7516873.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):247-53 [8797862.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29922-7 [8939936.001]
  • [Cites] Nature. 1997 Oct 9;389(6651):622-6 [9335505.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] Cell Tissue Res. 1999 May;296(2):221-7 [10382266.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9118-23 [10430905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):331-7 [15665311.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1131-41 [15635089.001]
  • [Cites] Nat Med. 2005 May;11(5):531-7 [15821746.001]
  • [Cites] Development. 2005 Jun;132(12):2759-70 [15901663.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6116-26 [16144910.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Cancer. 2006 May 1;106(9):1925-32 [16568440.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6312-8 [16778208.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1068-74 [16810241.001]
  • [Cites] Science. 2006 Jun 30;312(5782):1946-9 [16809539.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Int J Dev Biol. 2006;50(7):611-7 [16892174.001]
  • [Cites] Nat Rev Genet. 2008 Feb;9(2):115-28 [18202695.001]
  • [Cites] Cell. 2008 Feb 22;132(4):583-97 [18295577.001]
  • [Cites] Cell. 2008 Feb 22;132(4):598-611 [18295578.001]
  • [Cites] Cell. 2008 Feb 22;132(4):681-96 [18295583.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1881-8 [18339869.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):585-93 [18349276.001]
  • [Cites] Oncogene. 2008 Mar 20;27(13):1865-75 [17922036.001]
  • [Cites] PLoS One. 2008;3(4):e2025 [18431502.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1391-402 [18385519.001]
  • [Cites] Cell Res. 2008 May;18(5):523-7 [18392048.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 27;105(21):7546-51 [18495924.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W341-6 [18515841.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5716-23 [18632624.001]
  • [Cites] Biol Chem. 2008 Jul;389(7):897-903 [18681827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12469-73 [18711140.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8100-8 [16912187.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S79-83 [16958680.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • (PMID = 20040092.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806370
  •  go-up   go-down


75. Horvath G, Chilo J, Lindblad T: Different volatile signals emitted by human ovarian carcinoma and healthy tissue. Future Oncol; 2010 Jun;6(6):1043-9
Hazardous Substances Data Bank. TIN OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, it is essential to develop inexpensive and simple methods for early diagnosis.
  • The recorded signals were compared with healthy human Fallopian tube specimens.
  • CONCLUSION: Although based on a limited number of samples, our results strongly suggest that specific volatile organic compound signals emitted by ovarian carcinomas may be used for early diagnosis of the disease.
  • [MeSH-major] Adenocarcinoma, Papillary / chemistry. Biomarkers, Tumor / analysis. Fallopian Tubes / chemistry. Myometrium / chemistry. Ovarian Neoplasms / chemistry. Ovary / chemistry. Volatile Organic Compounds / analysis
  • [MeSH-minor] Algorithms. Early Diagnosis. Electric Impedance. Electrodes. Female. Humans. Odors. Pilot Projects. Postmenopause. Predictive Value of Tests. Semiconductors. Sensitivity and Specificity. Temperature. Tin Compounds

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TIN COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528240.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tin Compounds; 0 / Volatile Organic Compounds; 18282-10-5 / stannic oxide
  •  go-up   go-down


76. Abdulhathi MB, Al-Salam S, Kassis A, Ghazal-Aswad S: Unusual presentation of cervical cancer as advanced ovarian cancer. Arch Gynecol Obstet; 2007 Oct;276(4):387-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of cervical adenocarcinoma presenting primarily as advanced ovarian cancer with the primary site totally silent.
  • Right salpingo-oophorectomy was performed with the histologic diagnosis of dermoid cyst.
  • Surprisingly, the histologic features of the specimen obtained at laparotomy were consistent with a moderately differentiated cervical adenocarcinoma with metastases to corpus uterus, ovaries, left fallopian tube, omentum and pleural cavity.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


77. Hsu KH, Chou CY, Chang YC: Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei. Hepatogastroenterology; 2007 Jan-Feb;54(73):47-52
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The appendix was the origin of pseudomyxoma peritonei in 6 patients, the ovary in 1 patient, and the fallopian tube in another.
  • The pathologic diagnosis was mucinous adenocarcinoma in 4 patients, mucinous cystadenocarcinoma in 3, and mucinous cystadenoma in 1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419229.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All cancers were detected in asymptomatic women who had normal ultrasound and physical examinations 12 and 6 months before the cancer diagnosis.
  • The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


79. Chi DS, Barlin JN, Ramirez PT, Levenback CF, Mironov S, Sarasohn DM, Iyer RB, Dao F, Hricak H, Barakat RR: Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller. Int J Gynecol Cancer; 2010 Apr;20(3):353-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cystadenocarcinoma, Serous / surgery. Fallopian Tube Neoplasms / diagnosis. Neoplasm, Residual / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Postoperative Care. Prognosis. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375796.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol; 2006 Mar;107(3):701-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data showed the following rates of pathology: 8.5% low-grade squamous intraepithelial lesions (LSIL), 11.1% high-grade squamous intraepithelial lesions (HSIL), 2.9% adenocarcinoma in situ, 1.4% endometrial hyperplasia, and 5.2% malignancy.
  • The most common malignancies were endometrial adenocarcinoma (57.6%), cervical adenocarcinoma (23.6%), ovarian and fallopian tube carcinoma (6.4%), squamous cell carcinoma of the cervix (5.4%), and other (6.9%).
  • CONCLUSION: Histologic diagnosis showed that 29.0% of these Pap tests had findings requiring follow-up or therapeutic intervention, including a 5.2% rate of malignancy.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Hyperplasia / pathology. Uterine Cervical Neoplasms / pathology


81. Rose PG, Greer BE, Horowitz IR, Markman M, Fusco N: Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol; 2007 Jan;104(1):114-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Fallopian Tube Neoplasms / drug therapy. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959305.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


82. Khunamornpong S, Suprasert P, Chiangmai WN, Siriaunkgul S: Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:132-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The medical records, the radiologic findings, and the follow-up outcome in the cases suspicious or diagnostic of metastases were reviewed to confirm the diagnosis and to determine the primary sites.
  • Metastatic gynecologic tumors were from cervix (53%), corpus (34%), fallopian tube (11%), and gestational trophoblastic disease (2%).
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Ovarian Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515581.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Tan A, Argenta P, Ramirez R, Bliss R, Geller M: The use of sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier in gynecologic malignancies: a retrospective review of outcomes. Ann Surg Oncol; 2009 Feb;16(2):499-505
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 202 consecutive patients with epithelial ovarian, fallopian tube, and primary peritoneal cancer who underwent initial surgical staging or interval debulking at the University of Minnesota between January 2001 and December 2004.
  • Our retrospective analysis suggests that HA-CMC adhesion barrier does not affect disease-free survival or overall survival; nor does it increase the immediate postoperative complication rates in patients undergoing abdominal surgery for ovarian, fallopian tube, and primary peritoneal carcinomas.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / prevention & control. Adenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018596.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA077598-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membranes, Artificial; 0 / Seprafilm; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


84. Djordjevic B, Clement-Kruzel S, Atkinson NE, Malpica A: Nodal endosalpingiosis in ovarian serous tumors of low malignant potential with lymph node involvement: a case for a precursor lesion. Am J Surg Pathol; 2010 Oct;34(10):1442-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We first examined the frequency of nodal endosalpingiosis in 30 OSLMP cases, 30 cervical adenocarcinoma cases, and 30 endometrial endometrioid adenocarcinoma cases.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871218.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Vaysse C, Capdet J, Mery E, Querleu D: Paratubal endometrioid cystadenocarcinoma: case report and review. Eur J Gynaecol Oncol; 2009;30(4):443-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: To our knowledge, no case of paratubal invasive endometrioid adenocarcinoma has previously been described.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761142.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 11
  •  go-up   go-down


86. Silva EG, Young RH: Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol; 2007 Aug;31(8):1203-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of clear cells in genital tract neoplasms often reflexly prompts the diagnosis of a clear cell tumor but clear cells may be seen in many other neoplasms.
  • One tumor formed a cystic mass in the pelvis, 1 tumor involved the right fallopian tube, 1 the endometrium, and 18 the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2007 Oct;31(10):1628
  • (PMID = 17667544.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Olcha P, Cybulski M, Skomra D, Obrzut B, Ignatov A, Jóźwik M, Schneider-Stock R, Semczuk A: The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations. Int J Gynecol Cancer; 2010 Aug;20(6):993-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of primary cervical adenocarcinoma metastasizing to the lymph nodes showed p14(ARF) expression both in the primary tumor and the corresponding metastases.
  • A trend was found between the p14(ARF) expression in primary tumors and the presence of the neoplasms in the fallopian tube (P = 0.063), but none of the other clinicopathological variables of carcinoma was related to protein immunoreactivity in advanced-stage uterine neoplasms.
  • The p14(ARF) expression in EC metastases was related to the presence of the primary tumor in the fallopian tube (P = 0.036).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683407.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


88. Dhakal HP, Pradhan M: Histological pattern of gynecological cancers. JNMA J Nepal Med Assoc; 2009 Oct-Dec;48(176):301-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Out of total 1517 cases of gynecological cancers diagnosed, 1293 cases (85.23%) were cervical, 97 (6.39%) ovarian, 48 (3.16%) vulval, 41 (2.7%) vaginal, 32 (2.11%) endometrial cancers as well as 5 (0.33%) choriocarcinoma and 1 (0.07%) fallopian tube cancer.
  • Squamous cell carcinoma was the commonest histologic type in cervical, vaginal and vulval cancers whereas serous adenocarcinoma and endometrioid adenocarcinoma were commonest histological types in the ovary and endometrium respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105554.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


89. Hewitt MJ, Hall GD, Wilkinson N, Perren TJ, Lane G, Spencer JA: Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:108-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When women with a history of breast cancer present with peritoneal carcinomatosis, the differential diagnosis lies between recurrent breast cancer or a new primary tumor.
  • This scenario is of particular relevance to women with a BRCA gene mutation, who have a genetic predisposition to develop second primary tumors of the ovary, fallopian tube, and peritoneum.
  • We describe the use of image-guided core biopsy as an alternative to laparoscopy or exploratory laparotomy in providing minimally invasive diagnosis in this increasingly common clinical dilemma.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Mixed Tumor, Mullerian / pathology. Peritoneal Neoplasms / pathology. Peritoneum / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515576.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J: An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol; 2009 Apr;113(1):63-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Amifostine / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Outpatients. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Pilot Projects. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201457.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Nasir A, Boulware D, Kaiser HE, Lancaster JM, Coppola D, Smith PV, Hakam A, Siegel SE, Bodey B: Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo; 2007 Jan-Feb;21(1):35-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With an aim to demonstrate the expression and role of COX-2, the principal putative target of COX-2 inhibitor therapy, in endometrial adenocarcinoma (EACA) and precursor lesions, atypical complex hyperplasia (ACH) and endometrial hyperplasia (EH), an immunohistochemical (IHC) analysis of 22 primary human EACAs and 14 precursor lesions was carried out.
  • The areas of adenomyosis were COX-2 positive, while myometrial smooth muscle and normal fallopian tube tissues stained negative for COX-2.
  • [MeSH-major] Adenocarcinoma / enzymology. Cyclooxygenase 2 / metabolism. Endometrial Hyperplasia / enzymology. Endometrial Neoplasms / enzymology. Precancerous Conditions / enzymology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354612.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


92. Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M: A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. Am J Clin Oncol; 2008 Oct;31(5):476-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Administration, Oral. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / secondary. Feasibility Studies. Female. Humans. Maximum Tolerated Dose. Middle Aged. Polyethylene Glycols / administration & dosage. Prognosis. Survival Rate. Topotecan / administration & dosage

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838885.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


93. Huang KH, Chung SD, Huang SY, Chueh SC, Chen CA, Chen J: Coexistence of ovarian cancer and renal cell carcinoma. J Formos Med Assoc; 2007 Mar;106(3 Suppl):S15-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologic examination revealed right ovarian clear-cell carcinoma with peritoneal, omental, and fallopian tube metastasis, and conventional clear-cell renal carcinoma.


94. Soto-Cruz I, Rangel-Corona R, Valle-Mendiola A, Moreno-Morales X, Santiago-Pérez R, Weiss-Steider B, Cáceres-Cortés JR: The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. Cancer Invest; 2008 Mar;26(2):136-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Constitutive phosphorylation of HER-2 protein has been implicated in conferring uncontrolled growth to mammary cancer cells, and to a lesser extent, with adenocarcinoma of uterus, cervix, fallopian tube, and endometrium.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259943.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; 42HK56048U / Tyrosine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


95. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF Jr, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA, Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare: A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1035-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Women with ovarian, fallopian tube, or primary peritoneal carcinoma and documented recurrent disease were eligible for the study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Deoxycytidine / analogs & derivatives. Genital Neoplasms, Female / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343179.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


96. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z: High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics; 2009;2:21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A public expression array data set of laser capture micro-dissected (LCM) non-malignant fallopian tube epithelia and LCM ovarian serous adenocarcinoma was used to evaluate the effect of cell-type mixture biases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jan;46(1):1-9 [17044060.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1149-58 [16899652.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6312-8 [16778208.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4627-35 [16651413.001]
  • [Cites] Bioinformatics. 2006 Apr 1;22(7):849-56 [16434445.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):603-13 [16036111.001]
  • [Cites] Mol Carcinog. 2005 Jul;43(3):165-74 [15880741.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):590-2 [15908952.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):1859-75 [15728110.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Cell Oncol. 2005;27(1):57-65 [15750208.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3413-22 [15381628.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1251-6 [15502842.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8703-8 [9671742.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):3744-51 [9632757.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 1;154(1):16-21 [15381367.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4281-6 [12833150.001]
  • [Cites] Bioinformatics. 2002 Dec;18(12):1585-92 [12490442.001]
  • [Cites] Jpn J Cancer Res. 2002 Oct;93(10):1114-22 [12417041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4811-8 [14581352.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Oct;47(10):873-83 [18615678.001]
  • [Cites] Mol Cytogenet. 2008;1:10 [18492273.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jun;47(6):530-42 [18335499.001]
  • [Cites] Retrovirology. 2008;5:4 [18194563.001]
  • [Cites] Mol Cancer Res. 2008 Feb;6(2):212-21 [18314482.001]
  • [Cites] Genome Biol. 2007;8(10):R215 [17925008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5745-55 [17908964.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):511-8 [17503467.001]
  • [Cites] J Pathol. 2007 Sep;213(1):46-55 [17668415.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4731-9 [17699850.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3074-84 [17409414.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):145-6 [17344839.001]
  • [Cites] Methods Enzymol. 2006;411:256-70 [16939794.001]
  • (PMID = 19419571.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2694826
  •  go-up   go-down


97. Wang H, Chen PC: Primary serous peritoneal carcinoma presenting first on a routine papanicolaou smear: a case report. Acta Cytol; 2010 Jul-Aug;54(4):623-6
MedlinePlus Health Information. consumer health - Cervical Cancer Screening.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High grade adenocarcinoma was found by Pap smear.
  • Review of 9 cases showed tumor cells in the fallopian tube lumen in 4 out of 9 cases, indicating the likely route of efflux of tumor cells to appear in the Pap smear.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715668.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Jayashree K, Anubuti C, Sunila, Gundappa M: Primary fallopian tube adenocarcinoma with brain and lung metastasis. Indian J Pathol Microbiol; 2009 Oct-Dec;52(4):596-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma with brain and lung metastasis.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Brain Neoplasms / secondary. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / diagnosis. Lung Neoplasms / secondary. Neoplasm Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805996.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


99. Daaloul MW, Ben Hamouda S, Ben Zina H, Bouguerra B, Sfar R: [Carcinoma of the fallopian tube]. Tunis Med; 2008 Jan;86(1):84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the fallopian tube].
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472709.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


100. Huang WC, Yang SH, Yang JM: Ultrasonographic manifestations of fallopian tube carcinoma in the fimbriated end. J Ultrasound Med; 2005 Aug;24(8):1157-60; quiz 1161-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic manifestations of fallopian tube carcinoma in the fimbriated end.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Fallopian Tube Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040833.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement